United Kingdom News
Most Popular United Kingdom Story
NICE nixes Sanofi's Jevtana on cost, side effects
The U.K.'s cost-effectiveness watchdog has officially snubbed the Sanofi ($SNY) prostate cancer treatment Jevtana. The National Institute for Health and Clinical Excellence won't recommend the drug Read more...
Latest Headlines
- January 12, 2012
- January 3, 2012
- November 28, 2011
- November 4, 2011
- October 28, 2011
- October 10, 2011
- September 21, 2011
- September 13, 2011
- August 26, 2011
- July 15, 2011
- May 27, 2011
- April 21, 2011
- April 15, 2011
- March 17, 2011
- March 15, 2011
- March 3, 2011
- January 21, 2011
- January 12, 2011
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
